Open access
Sep 2026
RUNX2 inhibitor CADD522 improves bone microarchitecture and lipid metabolism in post-menopausal bone loss
Osteoporosis is a leading cause of age-related morbidity, yet existing antiresorptive and anabolic therapies remain limited by safety concerns, contraindications and poor long-term adherence. CADD522 is a small molecule inhibitor of the RUNX2 transcription factor currently under development for cancer therapy. Here, we...
A. Ersek, Myoung Sook Kim, Caterina M. Suelzu et al.
· npj Drug Discovery · 0 citations